epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.
EPI-301, Phase III. Recruiting
Non-small cell lung cancer, second line
NWT-4471 with docetaxel against docetaxel alone in previously treated non-small cell lung cancer. Sponsor: Northwind Therapeutics (fictional), Oncology.
Where EPI-301 stands on September 30th 2026
Randomised171of 400 needed
Sites open159of 159 planned
Median forecast finishAug 2027Deadline Jan 2028
FinishOn timeMedian forecast 5 months before the deadline.Open the plan
Enrolment82% of planRandomised to date against the count the plan expected by now.Open KPIs
Sites5 of 10 behindSites below their own expectation. The colour pools every site against what sites of their kind should recruit, so it changes only when the shortfall is more than chance.Open Sites
KRIs19 of 159 flaggedSites over at least one KRI threshold, each a candidate for a call, a targeted review or a visit.Open KRIs
QTLsAll 4 withinStudy-level quality limits, judged once enough patients are in.Open QTLs